| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Triple Negative Breast Neoplasms | 28 | 2025 | 169 | 7.670 |
Why?
|
| Breast Neoplasms | 69 | 2025 | 3021 | 5.980 |
Why?
|
| Neoadjuvant Therapy | 34 | 2025 | 374 | 3.640 |
Why?
|
| Receptor, ErbB-2 | 31 | 2025 | 247 | 3.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 38 | 2024 | 2503 | 2.620 |
Why?
|
| Antibodies, Monoclonal, Humanized | 15 | 2024 | 953 | 2.260 |
Why?
|
| Biomarkers, Tumor | 24 | 2025 | 1543 | 1.800 |
Why?
|
| Receptors, Estrogen | 13 | 2025 | 394 | 1.580 |
Why?
|
| Immunotherapy | 8 | 2025 | 693 | 1.390 |
Why?
|
| Programmed Cell Death 1 Receptor | 4 | 2024 | 172 | 1.350 |
Why?
|
| Immunoconjugates | 4 | 2024 | 114 | 1.340 |
Why?
|
| Receptors, Progesterone | 9 | 2025 | 175 | 1.230 |
Why?
|
| B7-H1 Antigen | 7 | 2024 | 278 | 1.210 |
Why?
|
| Neoplasm Staging | 21 | 2024 | 1998 | 1.210 |
Why?
|
| Female | 94 | 2025 | 46620 | 1.120 |
Why?
|
| Trastuzumab | 17 | 2024 | 73 | 1.080 |
Why?
|
| Complementary Therapies | 2 | 2024 | 56 | 1.080 |
Why?
|
| Camptothecin | 4 | 2024 | 195 | 1.080 |
Why?
|
| Paclitaxel | 13 | 2024 | 474 | 1.070 |
Why?
|
| Antineoplastic Agents | 9 | 2022 | 2328 | 0.990 |
Why?
|
| Antineoplastic Agents, Immunological | 4 | 2023 | 204 | 0.990 |
Why?
|
| Integrative Medicine | 1 | 2024 | 10 | 0.930 |
Why?
|
| Humans | 105 | 2025 | 90014 | 0.860 |
Why?
|
| Middle Aged | 59 | 2025 | 26179 | 0.800 |
Why?
|
| Tumor Microenvironment | 6 | 2024 | 475 | 0.780 |
Why?
|
| Adult | 50 | 2025 | 26845 | 0.690 |
Why?
|
| Aged | 44 | 2025 | 19269 | 0.680 |
Why?
|
| Neoplasm Metastasis | 15 | 2024 | 1065 | 0.670 |
Why?
|
| Genes, BRCA1 | 3 | 2011 | 192 | 0.630 |
Why?
|
| Age Factors | 1 | 2023 | 1879 | 0.610 |
Why?
|
| Pharmacogenetics | 5 | 2019 | 437 | 0.570 |
Why?
|
| Precision Medicine | 7 | 2023 | 412 | 0.570 |
Why?
|
| Circulating Tumor DNA | 3 | 2023 | 48 | 0.550 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2024 | 1350 | 0.550 |
Why?
|
| Capecitabine | 4 | 2024 | 93 | 0.540 |
Why?
|
| Receptors, Androgen | 3 | 2024 | 119 | 0.520 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 5 | 2021 | 76 | 0.510 |
Why?
|
| Antibodies, Monoclonal | 5 | 2024 | 1395 | 0.500 |
Why?
|
| Disease-Free Survival | 9 | 2024 | 1169 | 0.470 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2021 | 233 | 0.470 |
Why?
|
| Treatment Outcome | 19 | 2024 | 8295 | 0.460 |
Why?
|
| Clinical Decision-Making | 5 | 2021 | 281 | 0.450 |
Why?
|
| Quinazolines | 5 | 2023 | 212 | 0.390 |
Why?
|
| Prognosis | 13 | 2025 | 3794 | 0.380 |
Why?
|
| Genes, erbB-2 | 2 | 2009 | 25 | 0.370 |
Why?
|
| Breast | 7 | 2023 | 292 | 0.370 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 3 | 2023 | 64 | 0.360 |
Why?
|
| Piperazines | 3 | 2021 | 283 | 0.360 |
Why?
|
| Aged, 80 and over | 14 | 2024 | 6784 | 0.340 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2024 | 3480 | 0.320 |
Why?
|
| Mastectomy | 3 | 2018 | 246 | 0.320 |
Why?
|
| Receptors, Glucocorticoid | 2 | 2024 | 135 | 0.320 |
Why?
|
| Drug Prescriptions | 3 | 2019 | 141 | 0.310 |
Why?
|
| Gene Expression Profiling | 7 | 2025 | 1455 | 0.300 |
Why?
|
| Neoplasms | 5 | 2021 | 3065 | 0.300 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2020 | 70 | 0.290 |
Why?
|
| Retrospective Studies | 10 | 2025 | 9239 | 0.290 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2021 | 145 | 0.280 |
Why?
|
| Clinical Trials as Topic | 3 | 2022 | 1134 | 0.270 |
Why?
|
| Healthcare Disparities | 4 | 2025 | 432 | 0.270 |
Why?
|
| Benzimidazoles | 2 | 2017 | 107 | 0.260 |
Why?
|
| Cohort Studies | 6 | 2023 | 2886 | 0.260 |
Why?
|
| Carboplatin | 2 | 2017 | 311 | 0.250 |
Why?
|
| Hormones | 2 | 2023 | 139 | 0.250 |
Why?
|
| DNA Methylation | 5 | 2022 | 666 | 0.250 |
Why?
|
| Maytansine | 2 | 2021 | 10 | 0.240 |
Why?
|
| Molecular Targeted Therapy | 4 | 2021 | 280 | 0.240 |
Why?
|
| Genes, BRCA2 | 1 | 2005 | 161 | 0.240 |
Why?
|
| Sirolimus | 3 | 2014 | 162 | 0.220 |
Why?
|
| Phthalazines | 2 | 2021 | 46 | 0.220 |
Why?
|
| Mastectomy, Segmental | 1 | 2024 | 101 | 0.220 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2024 | 134 | 0.220 |
Why?
|
| Genetic Testing | 2 | 2018 | 543 | 0.220 |
Why?
|
| Survival Rate | 4 | 2021 | 1898 | 0.220 |
Why?
|
| Yoga | 1 | 2023 | 5 | 0.210 |
Why?
|
| Meditation | 1 | 2023 | 5 | 0.210 |
Why?
|
| Pharmacogenomic Testing | 3 | 2019 | 95 | 0.210 |
Why?
|
| Proteomics | 1 | 2024 | 232 | 0.210 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 160 | 0.210 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2022 | 57 | 0.200 |
Why?
|
| Anthracyclines | 1 | 2022 | 38 | 0.200 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2024 | 563 | 0.200 |
Why?
|
| United States | 6 | 2025 | 7115 | 0.190 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2023 | 83 | 0.190 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2024 | 314 | 0.190 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2024 | 476 | 0.190 |
Why?
|
| Doxorubicin | 4 | 2024 | 293 | 0.190 |
Why?
|
| Phenylthiohydantoin | 2 | 2019 | 46 | 0.190 |
Why?
|
| Contrast Media | 2 | 2023 | 1083 | 0.190 |
Why?
|
| Electron Transport Complex I | 1 | 2021 | 31 | 0.190 |
Why?
|
| Benzamides | 3 | 2019 | 234 | 0.180 |
Why?
|
| Specimen Handling | 1 | 2021 | 103 | 0.180 |
Why?
|
| Lymph Nodes | 1 | 2024 | 550 | 0.180 |
Why?
|
| Brain Neoplasms | 2 | 2018 | 782 | 0.180 |
Why?
|
| Telemedicine | 1 | 2023 | 195 | 0.180 |
Why?
|
| Homologous Recombination | 1 | 2020 | 53 | 0.180 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2020 | 36 | 0.170 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2020 | 201 | 0.170 |
Why?
|
| Germ-Line Mutation | 4 | 2020 | 347 | 0.170 |
Why?
|
| Point-of-Care Systems | 2 | 2019 | 146 | 0.170 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2017 | 102 | 0.170 |
Why?
|
| Imidazoles | 2 | 2019 | 140 | 0.170 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 540 | 0.160 |
Why?
|
| Pyridines | 1 | 2021 | 301 | 0.160 |
Why?
|
| Ovarian Neoplasms | 1 | 2005 | 771 | 0.160 |
Why?
|
| Prescription Drugs | 1 | 2019 | 34 | 0.160 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2018 | 36 | 0.150 |
Why?
|
| Cyclophosphamide | 3 | 2024 | 301 | 0.150 |
Why?
|
| Mutation | 8 | 2023 | 4169 | 0.150 |
Why?
|
| CTLA-4 Antigen | 1 | 2018 | 140 | 0.150 |
Why?
|
| Combined Modality Therapy | 5 | 2023 | 1703 | 0.150 |
Why?
|
| Genomics | 3 | 2024 | 778 | 0.150 |
Why?
|
| Radiosurgery | 1 | 2021 | 286 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2025 | 1284 | 0.150 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2014 | 160 | 0.140 |
Why?
|
| Albumins | 2 | 2015 | 129 | 0.140 |
Why?
|
| Medical Order Entry Systems | 1 | 2017 | 27 | 0.140 |
Why?
|
| BRCA1 Protein | 2 | 2017 | 205 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 2 | 2021 | 1055 | 0.140 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2017 | 137 | 0.140 |
Why?
|
| Neoplasm, Residual | 3 | 2023 | 182 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2019 | 587 | 0.130 |
Why?
|
| Dasatinib | 1 | 2016 | 38 | 0.130 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2016 | 71 | 0.130 |
Why?
|
| Diphosphonates | 1 | 2016 | 34 | 0.130 |
Why?
|
| BRCA2 Protein | 1 | 2017 | 161 | 0.130 |
Why?
|
| Quinolines | 1 | 2016 | 86 | 0.130 |
Why?
|
| DNA, Neoplasm | 1 | 2016 | 266 | 0.130 |
Why?
|
| Bone Density Conservation Agents | 1 | 2016 | 44 | 0.130 |
Why?
|
| Physician's Role | 1 | 2017 | 176 | 0.130 |
Why?
|
| Physician-Patient Relations | 2 | 2019 | 625 | 0.120 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2015 | 7 | 0.120 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2021 | 1253 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2014 | 405 | 0.120 |
Why?
|
| Mifepristone | 1 | 2014 | 33 | 0.120 |
Why?
|
| Meningeal Neoplasms | 1 | 2015 | 66 | 0.120 |
Why?
|
| Esophagitis | 1 | 2014 | 43 | 0.120 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2015 | 141 | 0.120 |
Why?
|
| Disease Progression | 4 | 2023 | 1468 | 0.110 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2014 | 97 | 0.110 |
Why?
|
| Genome, Human | 1 | 2019 | 792 | 0.110 |
Why?
|
| Nanoparticles | 1 | 2015 | 165 | 0.110 |
Why?
|
| Bone Neoplasms | 1 | 2016 | 321 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2014 | 693 | 0.110 |
Why?
|
| Follow-Up Studies | 4 | 2024 | 3682 | 0.110 |
Why?
|
| Bayes Theorem | 3 | 2024 | 382 | 0.110 |
Why?
|
| Radiation Injuries | 1 | 2014 | 160 | 0.110 |
Why?
|
| Proportional Hazards Models | 3 | 2020 | 846 | 0.100 |
Why?
|
| Young Adult | 6 | 2021 | 6423 | 0.100 |
Why?
|
| Immunohistochemistry | 4 | 2024 | 1801 | 0.100 |
Why?
|
| Nitriles | 3 | 2019 | 156 | 0.100 |
Why?
|
| Carcinoma in Situ | 1 | 2012 | 52 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 608 | 0.100 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 1731 | 0.090 |
Why?
|
| ErbB Receptors | 2 | 2011 | 499 | 0.090 |
Why?
|
| Kinetics | 2 | 2023 | 1535 | 0.090 |
Why?
|
| Macrophages | 1 | 2013 | 582 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2020 | 4326 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 3 | 2007 | 961 | 0.080 |
Why?
|
| Guidelines as Topic | 2 | 2021 | 158 | 0.080 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 293 | 0.080 |
Why?
|
| Logistic Models | 2 | 2016 | 1214 | 0.070 |
Why?
|
| Lymphatic Metastasis | 2 | 2024 | 496 | 0.070 |
Why?
|
| Fanconi Anemia Complementation Group F Protein | 1 | 2007 | 6 | 0.070 |
Why?
|
| Cell Line, Tumor | 3 | 2024 | 2588 | 0.070 |
Why?
|
| Maximum Tolerated Dose | 2 | 2021 | 263 | 0.070 |
Why?
|
| Transcriptome | 2 | 2023 | 666 | 0.070 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2007 | 173 | 0.070 |
Why?
|
| Estrogen Receptor alpha | 1 | 2007 | 148 | 0.070 |
Why?
|
| Animals | 3 | 2022 | 27551 | 0.070 |
Why?
|
| Genes, Neoplasm | 1 | 2006 | 38 | 0.070 |
Why?
|
| Patient Selection | 2 | 2021 | 682 | 0.070 |
Why?
|
| Epigenesis, Genetic | 3 | 2022 | 521 | 0.070 |
Why?
|
| Survival Analysis | 3 | 2018 | 1496 | 0.060 |
Why?
|
| Aneuploidy | 1 | 2005 | 57 | 0.060 |
Why?
|
| Disease Management | 2 | 2019 | 328 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2005 | 108 | 0.060 |
Why?
|
| Conserved Sequence | 1 | 2006 | 211 | 0.060 |
Why?
|
| Male | 8 | 2023 | 42705 | 0.060 |
Why?
|
| Probability | 1 | 2005 | 351 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2023 | 2018 | 0.060 |
Why?
|
| Receptor, TIE-2 | 1 | 2024 | 18 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2007 | 606 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2023 | 64 | 0.050 |
Why?
|
| Biology | 1 | 2023 | 52 | 0.050 |
Why?
|
| Liquid Biopsy | 1 | 2023 | 36 | 0.050 |
Why?
|
| Carcinoma, Lobular | 2 | 2014 | 81 | 0.050 |
Why?
|
| Biopsy | 2 | 2017 | 1185 | 0.050 |
Why?
|
| Demography | 1 | 2023 | 183 | 0.050 |
Why?
|
| Methylation | 1 | 2023 | 269 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2005 | 576 | 0.050 |
Why?
|
| Risk Factors | 2 | 2018 | 5566 | 0.050 |
Why?
|
| Amenorrhea | 1 | 2021 | 28 | 0.050 |
Why?
|
| Time Factors | 2 | 2021 | 5362 | 0.050 |
Why?
|
| Data Accuracy | 1 | 2021 | 32 | 0.050 |
Why?
|
| Drug Discovery | 2 | 2015 | 107 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 135 | 0.040 |
Why?
|
| Bridged-Ring Compounds | 1 | 2020 | 13 | 0.040 |
Why?
|
| Ferredoxin-NADP Reductase | 1 | 2020 | 15 | 0.040 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 27 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2023 | 462 | 0.040 |
Why?
|
| Oxazepines | 1 | 2019 | 4 | 0.040 |
Why?
|
| Taxoids | 1 | 2020 | 124 | 0.040 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2019 | 20 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 1081 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 528 | 0.040 |
Why?
|
| Postmenopause | 1 | 2020 | 102 | 0.040 |
Why?
|
| Drug Recalls | 1 | 2019 | 12 | 0.040 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2019 | 31 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 2014 | 568 | 0.040 |
Why?
|
| Receptors, Steroid | 1 | 2019 | 42 | 0.040 |
Why?
|
| Bevacizumab | 1 | 2020 | 267 | 0.040 |
Why?
|
| Everolimus | 1 | 2018 | 35 | 0.040 |
Why?
|
| Europe | 1 | 2019 | 324 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 491 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2018 | 69 | 0.040 |
Why?
|
| Research | 1 | 2019 | 251 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2021 | 584 | 0.040 |
Why?
|
| Pandemics | 1 | 2023 | 778 | 0.040 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2017 | 25 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 341 | 0.040 |
Why?
|
| Drug Labeling | 1 | 2017 | 40 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 181 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 1929 | 0.030 |
Why?
|
| California | 1 | 2017 | 146 | 0.030 |
Why?
|
| CpG Islands | 2 | 2007 | 158 | 0.030 |
Why?
|
| Health Personnel | 1 | 2019 | 214 | 0.030 |
Why?
|
| Social Perception | 1 | 2017 | 94 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2016 | 78 | 0.030 |
Why?
|
| src-Family Kinases | 1 | 2016 | 74 | 0.030 |
Why?
|
| Attitude to Health | 1 | 2017 | 222 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 853 | 0.030 |
Why?
|
| Vertical Dimension | 1 | 1995 | 1 | 0.030 |
Why?
|
| Orthodontics, Corrective | 1 | 1995 | 3 | 0.030 |
Why?
|
| Malocclusion | 1 | 1995 | 7 | 0.030 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2015 | 3 | 0.030 |
Why?
|
| Azacitidine | 2 | 2006 | 148 | 0.030 |
Why?
|
| Genotype | 1 | 2020 | 1854 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 688 | 0.030 |
Why?
|
| Communication | 1 | 2019 | 462 | 0.030 |
Why?
|
| Retreatment | 1 | 2015 | 107 | 0.030 |
Why?
|
| Cell Count | 1 | 2015 | 199 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 385 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2013 | 899 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2006 | 2360 | 0.030 |
Why?
|
| Alleles | 1 | 2017 | 1138 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2014 | 296 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 2327 | 0.030 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 21 | 0.030 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2013 | 33 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 338 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2013 | 44 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 437 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2014 | 343 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2013 | 114 | 0.030 |
Why?
|
| Chemoradiotherapy | 1 | 2015 | 305 | 0.030 |
Why?
|
| Triazoles | 1 | 2013 | 104 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2013 | 152 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 2416 | 0.020 |
Why?
|
| Quality of Life | 1 | 2020 | 1681 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2013 | 245 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 865 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 375 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 2658 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 726 | 0.020 |
Why?
|
| Neuroblastoma | 1 | 2014 | 400 | 0.020 |
Why?
|
| DNA-Binding Proteins | 2 | 2006 | 1243 | 0.020 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2014 | 399 | 0.020 |
Why?
|
| Adolescent | 2 | 2020 | 9352 | 0.020 |
Why?
|
| Senegal | 1 | 2009 | 4 | 0.020 |
Why?
|
| Nigeria | 1 | 2009 | 157 | 0.020 |
Why?
|
| Health Surveys | 1 | 2009 | 240 | 0.020 |
Why?
|
| Apoptosis | 1 | 2015 | 1718 | 0.020 |
Why?
|
| Transcription Factors | 2 | 2006 | 1670 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2014 | 755 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2008 | 476 | 0.020 |
Why?
|
| Cyclin A1 | 1 | 2006 | 2 | 0.020 |
Why?
|
| Cathepsin K | 1 | 2006 | 3 | 0.020 |
Why?
|
| MSX1 Transcription Factor | 1 | 2006 | 3 | 0.020 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2006 | 12 | 0.020 |
Why?
|
| Cyclin A | 1 | 2006 | 29 | 0.020 |
Why?
|
| Cathepsins | 1 | 2006 | 21 | 0.020 |
Why?
|
| DNA Modification Methylases | 1 | 2006 | 28 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 1221 | 0.020 |
Why?
|
| DNA Repair | 1 | 2008 | 363 | 0.020 |
Why?
|
| Keratin-5 | 1 | 2006 | 3 | 0.020 |
Why?
|
| Keratin-6 | 1 | 2006 | 3 | 0.020 |
Why?
|
| Keratins | 1 | 2006 | 63 | 0.020 |
Why?
|
| Neprilysin | 1 | 2006 | 41 | 0.020 |
Why?
|
| Vimentin | 1 | 2006 | 46 | 0.020 |
Why?
|
| Sample Size | 1 | 2006 | 125 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2005 | 50 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 885 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2006 | 154 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2006 | 371 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2005 | 210 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2006 | 1048 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2006 | 261 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 2006 | 355 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2006 | 290 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2005 | 468 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2006 | 443 | 0.010 |
Why?
|
| Actins | 1 | 2006 | 462 | 0.010 |
Why?
|
| Research Design | 1 | 2006 | 591 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2006 | 571 | 0.010 |
Why?
|
| Gene Expression | 1 | 2005 | 1309 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2006 | 1096 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 2769 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 2026 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2006 | 1183 | 0.010 |
Why?
|
| Phenotype | 1 | 2006 | 2458 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2006 | 2360 | 0.010 |
Why?
|
| Malocclusion, Angle Class I | 1 | 1995 | 1 | 0.010 |
Why?
|
| Malocclusion, Angle Class II | 1 | 1995 | 1 | 0.010 |
Why?
|
| Mesial Movement of Teeth | 1 | 1995 | 1 | 0.010 |
Why?
|
| Incisor | 1 | 1995 | 7 | 0.010 |
Why?
|
| Tooth Extraction | 1 | 1995 | 11 | 0.010 |
Why?
|
| Cephalometry | 1 | 1995 | 50 | 0.010 |
Why?
|
| Molar | 1 | 1995 | 22 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2006 | 1746 | 0.010 |
Why?
|
| Child | 1 | 1995 | 7241 | 0.000 |
Why?
|